Loading...
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
BACKGROUND: Patients with severe COVID-19 develop a life-threatening hyperinflammatory response to the virus. Interleukin (IL)-1 or IL-6 inhibitors have been used to treat this patient population, but the comparative effectiveness of these different strategies remains undetermined. We aimed to compa...
Na minha lista:
| Udgivet i: | Lancet Rheumatol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier Ltd.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7906668/ https://ncbi.nlm.nih.gov/pubmed/33655218 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2665-9913(21)00012-6 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|